Conference Day 2

Explore our agenda to see all sessions, timings, and full speaker details for this year's Gastrointestinal Cancer Drug Development Summit.

All agenda timings below are displayed in EST. For PST, please download the full program here.

8:00 am Online Networking Coffee

8:20 am Chair’s Opening Remarks

Rational Drug Development to Address Tumor Resistance Mechanisms

8:30 am FGFR2 Fusions: Addressing Clinically Relevant Secondary Mutations

  • Eric Murphy Co-Founder & Chief Scientific Officer, Kinnate Biopharma Inc.

Synopsis

  • FGFR2 alterations are known oncogenic drivers in intrahepatic cholangiocarcinoma (iCCA) with fusions or rearrangements detected in > 10% of patients
  • Preclinical studies with KIN-3248, an irreversible pan-FGFR inhibitor, demonstrate inhibition across the full spectrum of clinically relevant FGFR2 secondary resistance mutations observed in iCCA
  • Duration of response may be improved by targeting known FGFR2 secondary resistance mechanisms to approved FGFR inhibitors and will be explored in clinical studies of KIN-3248 in FGFR2-altered iCCA

8:55 am Targeting RAS Mutant GI Cancers – Treatment Strategies and Resistance Mechanisms

Synopsis

  • Unmet medical need in RAS mutant GI cancers
  • RAS(ON) Targeted Therapies for RAS mutant GI cancers: mutantselective and RASMulti inhibitors
  • Application of biomarker-driven combination strategies

9:20 am Speaker Q&A

  • Eric Murphy Co-Founder & Chief Scientific Officer, Kinnate Biopharma Inc.
  • Mallika Singh VP, Translational Research, Revolution Medicines

9:30 am Morning Networking Break

Developing a Clinical Program for ADCs to Progress Your Candidate

10:00 am Developing ADCs For HER2-Positive Gastric Cancer: Pivotal Research Efforts Made in GI Cancers & The Next Steps For Novel Approaches

10:25 am Precision Chemo Radiotherapy Using ADCs in GI Cancers

Synopsis

  • Advantages of concurrent chemo-radiotherapy
  • Specificity of the target
  • Careful selection of drug, impact of bystander effect

10:50 am Anti-FGFR2 ADC For Potential Treatment Of Gastroesophageal Cancers

  • Amy Han Solid Tumor Targeted Therapies & Commercial Disease Area Leader, Regeneron

11:15 am Speaker Q&A

  • Nataliya Uboha Assistant Professor, University of Wisconsin-Madison
  • Dina Hingorani Senior Scientist, Seagen
  • Amy Han Solid Tumor Targeted Therapies & Commercial Disease Area Leader, Regeneron

11:30 am Panel Discussion – Clinical Program Development Takeaways: How Can Researchers & Drug Developers in Any Targeted, Immune, Chemo, ADC Therapies Unite & Collaborate Future Directions to Optimize Our Own Drugs & Overall Patient Outlook?

  • Mallika Singh VP, Translational Research, Revolution Medicines
  • Ting Xu Chairman, Chief Executive Offier, Executive Director & Founder, Alphamab Oncology
  • Edward Cha Global Development Lead, GI CANCERS & COMBINATIONS, Genentech
  • Eric Murphy Co-Founder & Chief Scientific Officer, Kinnate Biopharma Inc.

Synopsis

  • Learnings from the past, how have we each developed our drugs considering previous work published?
  • How can we optimize our program for any of the GI Cancer Indications?
  • Thoughts on translating an established candidate from another solid tumor into GI cancer
  • Utilizing patient groups, precision oncology & early detection in our clinical programs

12:00 pm Online Networking Lunch

Building an Effective Clinical Trial Program in GI Cancer

1:00 pm Strategies to Optimize Timely Patient Identification & Accrual for Clinical Trials

  • Afsaneh Barzi Associate Professor of Medical Oncology & Chief Medical Advisor, City of Hope-Director of Employer Health & Access-Hope Cardiff Oncology

Synopsis

  • Heterogeneity populations and outcomes of the diseases in the GI portfolio
  • Patient experience with cancer and its impact on the treatment
  • Provider experience with the patient population and treatment selection

1:25 pm Can Technology Make Clinical Trials More Diverse & Representative?

  • Muhammad Shaalan Beg Associate Professor & Assistant Director - Gastrointestinal Medical & Oncology, Internal Medicine, Gastrointestinal Co-Leader, UT Southwestern

Synopsis

  • The current clinical trial infrastructure does not serve our patients well
  • Advances in technology and virtual care are poised to change how we perform clinical trials
  • Pancreatic cancer and other GI cancers are the ideal model to test a new paradigm in clinical trials

1:50 pm Speaker Q&A

  • Elizabeth Smyth Clinical Consultant - Department of Oncology, Cambridge University Hospitals NHS Foundation Trust
  • Muhammad Shaalan Beg Associate Professor & Assistant Director - Gastrointestinal Medical & Oncology, Internal Medicine, Gastrointestinal Co-Leader, UT Southwestern
  • Afsaneh Barzi Associate Professor of Medical Oncology & Chief Medical Advisor, City of Hope-Director of Employer Health & Access-Hope Cardiff Oncology

2:00 pm Afternoon Networking Break

2:30 pm Panel Discussion – Diversity & Inclusion in Oncological Drug Development – How Can We Not Only Make Clinical Trials More Representative But The Entire Pharmaceutical Workforce To Increase Productivity From Within?

  • Kamala K Maddali President & Founder, Health Collaborations LLC
  • Muhammad Shaalan Beg Associate Professor & Assistant Director - Gastrointestinal Medical & Oncology, Internal Medicine, Gastrointestinal Co-Leader, UT Southwestern

Optimizing Clinical Practice, Early Detection & Precision Oncology to Improve Patient Outlook

3:00 pm Tracking Quality in GI Cancer Screening Programs for Early Detection & Improved Outcomes

  • David A. Leiman Assistant Professor of Medicine, Director, Esophageal Research & Quality Division of Gastroenterology, Duke University Medical Center Duke Clinical Research Institute

3:25 pm Artificial Intelligence’s Role in Adoption of Precision Medicine Innovation

Synopsis

  • Advancements in precision medicine-overview of diagnostics and therapies
  • Industry overview on clinical trials in precision medicine
  • Challenges in adoption of approved treatments, current trials, and diagnostics
  • Role of artificial intelligence in adoption of precision medicine innovation from trials to therapies
  • Case studies and prospects

3:50 pm BloodPAC Consortium: Accelerating Development, Approval & Accessibility

Synopsis

  • Developing BloodPAC: a collaboration to compete and accelerate progress in the liquid biopsy field
  • Evidence generation: defining standards and guidelines to benefit stakeholders
  • BloodPAC data commons: aggregating data to support standards for the community
  • Stakeholder engagement: Where do we go from here? Reimbursement and accessibillity for patient benefit

4:15 pm Speaker Q&A and Open Discussion

  • David A. Leiman Assistant Professor of Medicine, Director, Esophageal Research & Quality Division of Gastroenterology, Duke University Medical Center Duke Clinical Research Institute
  • Kamala K Maddali President & Founder, Health Collaborations LLC
  • Lauren Leiman Executive Director, BloodPAC

4:45 pm Chair’s Closing Remarks

5:00 pm End Of Conference